Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Myeloma Crowd Radio

Myeloma Crowd Radio


Follow This Show

Stay in the know about new episodes and updates.
Myeloma Crowd Radio brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.

On-Demand Episodes

Nanotecnology is the study of very small things - won to the atom and molecule level. Researchers at Washingon University have been given a prestigious grant by the NIH to study nanotechnology in cancer and more specifcially, in... more

You may have heard about checkpoint inhibitors - drugs that help take the breaks off the immune system to fight multiple myeloma. Learn more about how this new class of drugs is being used with all types of myeloma treatment and when they... more

The Institute for Clinical and Economic Review's (ICER) Midwest Comparative Effective Public Advisory Council (CEPAC) will hold is inaugural meeting on May 26, 2016 in St. Louis ?to discuss the comparative clinical effectiveness... more

While immunotherapy approaches expand, proteasome inhibitors remain a staple therapy of multiple myeloma. Learn why they work, how they differ, how the new oral version (Ninlaro) is bringing greater convenience to the clinic, why they... more

Myeloma stem cells are believed to cause the growth of multiple myeloma. Many myeloma treatments kill the myeloma plasma cells, but according to William Matsui, MD of the Johns Hopkins Kimmel Cancer Center, these treatments may... more

Melanie House, DPT, NCS of the University of Iowa recently presented at Pat's Myeloma Survival School on physical issues that myeloma patients face before, during and after their treatment. As part of the Muscles for Myeloma series, she... more

The multiple myeloma aresenal is growing, giving myeloma experts more tools to combat the complex blood cancer, multiple myeloma. Learn how investigators like Dr. David Siegel, MD, PhD of the John Theurer Cancer Center are vetting... more

Can we prevent smoldering myeloma or MGUS from progressing to active myeloma? Dr. Irene Ghobrial, MD wonders why we are waiting until progression to treat when we have newer non-toxic therapies to use. Dr. Ghobrial... more

Immunotherapy combinations are just beginning. At the ASH 2015 conference Dr. David Avigan, MD of the Beth Israel Deaconess Medical Center shared his work to use a vaccine with an additional immunotherapy (a PD-1 blocker) and... more

Some treatments for multiple myeloma have been used for over two decades. With all of excitement around new treatments like immunotherapies, how do these two different worlds converge or collide? Learn from Dr. Muzaffar Qazilbash,... more
Show Extras